维立志博-B(09887):LBL-047取得美国FDA的IND批准

智通财经
Sep 22, 2025

智通财经APP讯,维立志博-B(09887)发布公告,美国食品药品监督管理局(美国FDA)已于2025年9月19日批准其自主研发药物LBL-047的新药临床试验(IND)申请。LBL-047是一种由人源化抗血液树突状细胞抗塬2(BDCA2)抗体及经改造的跨膜激活剂和钙调亲环素配体相互作用分子(TACI)胞外域组成的双特异性融合蛋白。目前全球范围内尚无同时靶向BDCA2及TACI的融合蛋白获批或处于临床阶段,表明LBL-047具有同类第一的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10